- Home
- SAGE vs IGD Comparison
SAGE vs IGD Comparison
Compare SAGE & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- IGD
- Stock Information
- Founded
- SAGE 2010
- IGD N/A
- Country
- SAGE United States
- IGD United States
- Employees
- SAGE N/A
- IGD N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- IGD Trusts Except Educational Religious and Charitable
- Sector
- SAGE Health Care
- IGD Finance
- Exchange
- SAGE Nasdaq
- IGD Nasdaq
- Market Cap
- SAGE 444.1M
- IGD 432.2M
- IPO Year
- SAGE 2014
- IGD N/A
- Fundamental
- Price
- SAGE $7.31
- IGD $5.51
- Analyst Decision
- SAGE Hold
- IGD
- Analyst Count
- SAGE 20
- IGD 0
- Target Price
- SAGE $10.67
- IGD N/A
- AVG Volume (30 Days)
- SAGE 1.8M
- IGD 215.3K
- Earning Date
- SAGE 02-11-2025
- IGD 01-01-0001
- Dividend Yield
- SAGE N/A
- IGD 9.15%
- EPS Growth
- SAGE N/A
- IGD N/A
- EPS
- SAGE N/A
- IGD N/A
- Revenue
- SAGE $41,243,000.00
- IGD N/A
- Revenue This Year
- SAGE $123.13
- IGD N/A
- Revenue Next Year
- SAGE $69.65
- IGD N/A
- P/E Ratio
- SAGE N/A
- IGD N/A
- Revenue Growth
- SAGE N/A
- IGD N/A
- 52 Week Low
- SAGE $4.62
- IGD $4.60
- 52 Week High
- SAGE $23.22
- IGD $5.26
- Technical
- Relative Strength Index (RSI)
- SAGE 60.55
- IGD 55.46
- Support Level
- SAGE $7.00
- IGD $5.31
- Resistance Level
- SAGE $7.26
- IGD $5.47
- Average True Range (ATR)
- SAGE 0.19
- IGD 0.05
- MACD
- SAGE -0.06
- IGD 0.01
- Stochastic Oscillator
- SAGE 57.14
- IGD 88.64
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.